Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant respiratory syncytial virus vaccine
- Development stage
- Phase 3
- Lead developer
- MAXVAX Biotechnology
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The recombinant respiratory syncytial virus vaccine is a biological product developed by MAXVAX Biotechnology Limited Liability Company. It is designed to evaluate its safety and immunogenicity in healthy adults aged 18 years and above. The vaccine is administered intramuscularly and is produced using CHO cells.
- Other names
- Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)
Beyond the preview
Go deeper on recombinant respiratory syncytial virus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant respiratory syncytial virus vaccine.